Stocks of Edwards Lifesciences Corp (NYSE:EW) traded higher last session on Wall Street, up 2.40% to $71.27.
According to the data, Edwards Lifesciences Corp (NYSE:EW) has 30 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $110.00 and a low of $75.00, we find $95.00. Given the previous closing price of $69.60, this indicates a potential upside of 36.49 percent. EW stock price is now -6.76% away from the 50-day moving average and -12.43% away from the 200-day moving average. The market capitalization of the company currently stands at $43.33B.
A total of 12 analysts have issued a hold rating and 14 have given it a buy rating. Brokers who have rated the stock have averaged $95.32 as their price target over the next twelve months.
With the price target maintained at $90, Oppenheimer recently Upgraded its rating from Perform to Outperform for Edwards Lifesciences Corp (NYSE: EW).
In other news, Chopra Daveen, CVP, TMTT sold 8,500 shares of the company’s stock on Oct 03. The stock was sold for $595,000 at an average price of $70.00. Upon completion of the transaction, the CVP, TMTT now directly owns 23,950 shares in the company, valued at $1.71 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 02, Director MUSSALLEM MICHAEL A sold 29,350 shares of the business’s stock. A total of $2,020,454 was realized by selling the stock at an average price of $68.84. This leaves the insider owning 4,486 shares of the company worth $0.32 million. Insiders disposed of 844,680 shares of company stock worth roughly $60.2 million over the past 1 year. A total of 1.09% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EW stock. A new stake in Edwards Lifesciences Corp shares was purchased by STONEHAGE FLEMING FINANCIAL SERVICES HOLDINGS LTD during the first quarter worth $86,344,000. BOWEN HANES & CO INC invested $25,311,000 in shares of EW during the first quarter. In the first quarter, UNISUPER MANAGEMENT PTY LTD acquired a new stake in Edwards Lifesciences Corp valued at approximately $14,271,000. ALPHINITY INVESTMENT MANAGEMENT PTY LTD acquired a new stake in EW for approximately $12,601,000. RETIREMENT SYSTEMS OF ALABAMA purchased a new stake in EW valued at around $9,820,000 in the second quarter. In total, there are 1,798 active investors with 85.07% ownership of the company’s stock.
Wednesday’s opening bell rang with an opening price of $69.79 for Edwards Lifesciences Corp (NYSE: EW). During the past 12 months, Edwards Lifesciences Corp has had a low of $67.13 and a high of $94.87. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 3.15, and a quick ratio of 2.30. According to the stock market information, the enterprise value for the company is $41.49B, which is based on a 31.57 price-to-earnings ratio, a 3.26 price-to-earnings-growth ratio, and a beta of 1.01. The fifty day moving average price for EW is $76.03 and a two-hundred day moving average price translates $81.37 for the stock.
The latest earnings results from Edwards Lifesciences Corp (NYSE: EW) was released for Jun, 2023. The net profit margin was 24.56% and return on equity was 22.56% for EW. The company reported revenue of $1.53 billion for the quarter, compared to $1.37 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.38 percent.
